`LUCENT lS
`su,ine$S Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Minutes
`
`Meeting Date: Aug 20 2012
`Meeting Notes Date: Aug. 27
`Author:
`Room: WSJ-340.3.09
`
`Dial-in: p
`
`Tclcccrtcrma,s.lll'ig
`
`Team Members : (✓ = Present, •= part-time)
`
`Team Members:(✓ = Present, • = part-time)
`I Name
`
`Executive summary ·(cid:173)· (cid:173)· -I
`
`I·
`
`Ii
`
`TRO S<Jbteam Meeling: Date of Meeting: August 20. 20 12
`
`1of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Toplc/SituatioM Ptoject Update
`
`None
`
`Discussion
`
`Achievements
`
`Issues
`
`Actions
`What
`
`§
`
`Topic/Situation
`
`Discus-sf on
`
`Who
`
`When
`
`----
`
`~.
`
`ill
`
`TRO S<Jbteam Meeling: Date of Meeting: August 20, 20 12
`
`2of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Achi.evements
`
`Issues
`Whal
`
`Actions
`Whal
`
`Topic/Situation
`
`I=
`
`Achievements
`
`Issues
`What
`
`Act1ons
`Whal
`
`J
`
`o en
`
`Who
`
`Close<!
`
`When
`
`.Lead:
`
`Pre-reads
`
`None
`
`0 n
`
`Closed
`
`I Lead:
`
`TRO S<Jbteam Meeling: Date of Meeting; August 20, 20 12
`
`3 of 10
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Pre-reads
`
`None
`
`0 . n
`
`Who
`
`Closed
`
`When
`
`Achi'evements
`
`Issues
`What
`
`Actions
`What
`
`r opic/Situation
`
`I ■ ·-
`
`TRO S<Jbtea m Meeling: Date of Meeting: August 20, 20 12
`
`4 of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.004
`Regeneron v. Novartis, IPR2021-008 16
`
`
`
`Achievements
`
`Issues
`
`0 n
`
`Closed
`
`TRO S<Jbteam Meeling: Date of Meeting: August 20, 20 12
`
`5of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Ols.cussion
`
`Achievements
`
`Issues
`What
`
`Topic/Situation
`
`Qiscussion
`
`0 en
`
`Closed
`
`Pre-reads
`
`None
`
`TRO S<Jbteam Meeling: Date of Meeting: August 20, 20 12
`
`6of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.006
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`Achievements
`
`Issues
`What
`
`Actions
`What
`
`Topic/Situation
`
`Discussion
`
`Open
`
`Who
`
`Closed
`
`When
`
`Pre-reads
`
`None
`
`TRO S<Jbteam Meeling: Date of Meeting: August 20, 20 12
`
`7of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.007
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Achievements
`
`Issues
`l--'W-'-'h=at' - - - - - - - - - - - - - - -1.2f.>=en'-------+-'-c _1os'--e-'-'d. ___ --1
`
`Actions
`What
`
`When
`
`TRO S<Jbteam Meeling: Date of Meeting: August 20, 20 12
`
`8of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.008
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`Consolidated Action Plan
`
`Who
`
`When --- --
`
`TRO S<Jbteam Meeling: Date of Meeting: August 20, 20 12
`
`9of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.009
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`TRO S<Jbteam Meeling: Date of Meeting: Aug ust 20, 20 12
`
`t0of 10
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2083.0010
`Regeneron v. Novartis, IPR2021 -00816
`
`